These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7165319)

  • 21. Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
    Studer-Sachsenberg EM; Piletta PA; Fathi M; Saurat JH; Salomon D
    Dermatology; 1997; 195(1):81-3. PubMed ID: 9267751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psoralen phototoxicity: correlation with serum and epidermal 8-methoxypsoralen and 5-methoxypsoralen in the guinea pig.
    Kornhauser A; Wamer WG; Giles AL
    Science; 1982 Aug; 217(4561):733-5. PubMed ID: 7100920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of the skin concentrations after administration of the various phototoxic drugs.
    Park YK; Hann SK; Cho MY; Kim HJ; Shim SC; Choi SJ; Yun MH
    Yonsei Med J; 1991 Sep; 32(3):231-6. PubMed ID: 1781182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parenteral administration of 8-methoxypsoralen in photopheresis.
    Knobler RM; Trautinger F; Graninger W; Macheiner W; Gruenwald C; Neumann R; Ramer W
    J Am Acad Dermatol; 1993 Apr; 28(4):580-4. PubMed ID: 8463458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum and urine concentrations of 5-methoxypsoralen after oral administration.
    Stolk LM; Westerhof W; Cormane RH; van Zwieten PA
    Br J Dermatol; 1981 Oct; 105(4):415-9. PubMed ID: 7295552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation.
    Aubin F; Makki S; Humbert P; Muret P; Agache P
    Arch Dermatol Res; 1994; 286(1):30-4. PubMed ID: 8141609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dietary intake and risk assessment of phototoxic furocoumarins in humans.
    Schlatter J; Zimmerli B; Dick R; Panizzon R; Schlatter C
    Food Chem Toxicol; 1991 Aug; 29(8):523-30. PubMed ID: 1894218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
    George SA; Ferguson J
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M; Ros AM
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Technical experience with 8-methoxypsoralen photochemotherapy in common psoriasis].
    Hofmann C; Plewig G; Braun-Falco O
    Hautarzt; 1976 Jun; 27(6):277-85. PubMed ID: 950302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment.
    Sakuntabhai A; Diffey BL; Farr PM
    Br J Dermatol; 1995 Dec; 133(6):919-23. PubMed ID: 8547045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose dependent inhibitory effects of dietary 8-methoxypsoralen on NNK-induced lung tumorigenesis in female A/J mice.
    Takeuchi H; Saoo K; Matsuda Y; Yokohira M; Yamakawa K; Zeng Y; Miyazaki M; Fujieda M; Kamataki T; Imaida K
    Cancer Lett; 2006 Mar; 234(2):232-8. PubMed ID: 15893417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with meladinin tablets.
    Thune P
    Acta Derm Venereol; 1978; 58(2):149-51. PubMed ID: 76395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [5-Methoxypsoralen: bioavailability and pharmacokinetics].
    Nitsche V; Mascher H
    Arzneimittelforschung; 1982; 32(10):1338-41. PubMed ID: 6891237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microenema of 8-methoxypsoralen in photochemotherapy of psoriasis.
    Siddiqui AH; Stolk L; Korthals Altes-Levij van Vinninghe HR; Kammeijer A; Cormane RH
    Arch Dermatol Res; 1982; 273(3-4):219-23. PubMed ID: 7165351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum level profiles of 8-methoxypsoralen after oral administration.
    Steiner I; Prey T; Gschnait F; Washüttl J; Greiter F
    Arch Dermatol Res (1975); 1977 Sep; 259(3):299-301. PubMed ID: 911196
    [No Abstract]   [Full Text] [Related]  

  • 37. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
    Nørgaard M; Hueg B; Staberg B
    Photodermatol; 1985 Aug; 2(4):252-6. PubMed ID: 3903679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Methoxy psoralen, etretinate, and UVA for psoriasis.
    Lane-Brown M
    Int J Dermatol; 1987 Dec; 26(10):655-9. PubMed ID: 3429102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration.
    Grundmann-Kollmann M; Podda M; Bräutigam L; Hardt-Weinelt K; Ludwig RJ; Geisslinger G; Kaufmann R; Tegeder I
    Br J Clin Pharmacol; 2002 Nov; 54(5):535-9. PubMed ID: 12445034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and metabolite-pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dog.
    Busch U; Schmid J; Koss FW; Zipp H; Zimmer A
    Arch Dermatol Res; 1978 Aug; 262(3):255-65. PubMed ID: 718254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.